Overview

Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase Alfa

Status:
Recruiting
Trial end date:
2027-08-31
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to assess the efficacy of ALXN1850 versus placebo on functional outcomes in adolescent and adult participants with HPP who have not previously been treated with asfotase alfa.
Phase:
Phase 3
Details
Lead Sponsor:
Alexion Pharmaceuticals, Inc.